Welcome to our dedicated page for Provectus Biopha SEC filings (Ticker: PVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Provectus Biopharmaceuticals, Inc. (PVCT) SEC filings page on Stock Titan is intended to centralize access to the company’s U.S. regulatory disclosures as they become available, alongside AI-generated insights. Provectus describes itself as a clinical-stage biotechnology company developing immunotherapy medicines based on halogenated xanthenes, led by its rose bengal sodium platform and investigational drug PV-10. For investors and researchers, SEC documents are a key source of information on how this scientific and clinical activity is reflected in the company’s formal reporting.
While no specific filings are listed in the data provided here, typical SEC reports for a company like Provectus can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, as well as proxy statements related to annual stockholder meetings. These documents may discuss clinical trial progress, research collaborations, risk factors, financing activities, and other matters relevant to a clinical-stage biotechnology business focused on oncology, dermatology, ophthalmology, wound healing, hematology, infectious diseases, and tissue repair research.
Stock Titan’s platform enhances these filings with AI-powered summaries designed to explain complex sections in clearer language. When filings are available, users can quickly see highlights from lengthy reports, such as key updates on investigational programs like PV-10, descriptions of the rose bengal sodium-based pipeline, and discussions of corporate structure or founded entities such as VisiRose. The platform also supports real-time updates as new SEC documents are posted to the EDGAR system.
For those analyzing PVCT, this page offers a single location to review Provectus’s regulatory history as it is reported, with tools that help interpret dense disclosures and place them in the context of the company’s stated focus on halogenated xanthene-based immunotherapy medicines.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted a 2024 unsecured convertible promissory note into equity on September 19, 2025. The $100,000 8% note, originally issued under the companys 2024 financing and convertible at $2.862 per share into Series D-1 Preferred Stock, converted into 37,760 shares of Series D-1 Preferred Stock on that date. Each Series D-1 share is convertible into ten shares of common stock, so the conversion corresponds to 377,600 shares of common stock. Following the transaction, Mr. Pershing beneficially owned 2,418,447 shares of common stock. The Series D-1 will automatically convert to common on June 20, 2026 unless earlier converted under its terms.
Insider transaction summary: The company's CEO and a director, Edward Pershing, acquired an 8% unsecured convertible promissory note with a principal amount of $35,000 issued under the issuer's 2025 financing, which is convertible at $2.862 per share into Series D-1 Convertible Preferred Stock. The note may be voluntarily converted at any time while outstanding and will automatically convert into Series D-1 Preferred Stock one year after issuance. Each Series D-1 Preferred share converts into 10 shares of common stock, and the reported Series D-1 Preferred position equals 12,230 shares (effectively 122,300 common shares if converted). The Series D-1 Preferred will automatically convert into common on the specified conversion date absent earlier conversion.
Edward Pershing, CEO and Director of Provectus Biopharmaceuticals (PVCT), reported a transaction dated 09/11/2025. He acquired an 8% unsecured convertible promissory note with a principal amount of $35,000 that is convertible into Series D-1 Convertible Preferred Stock at a conversion price of $2.862 per share. Following the reported transaction he beneficially owns 12,230 shares of Series D-1 Preferred Stock. Each Series D-1 Preferred share is convertible into 10 shares of common stock, and the Series D-1 Preferred will automatically convert into common stock on June 26, 2026 unless converted earlier. The Note will automatically convert into Series D-1 Preferred twelve months after issuance if not voluntarily converted earlier.